Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: A preliminary study

NeuroImage

Volumn 49, Issue 3, 2010, Pages 2783-2790

  Shirayama, Yukihiko ^a   Obata, Takayuki ^b   Matsuzawa, Daisuke ^a   Nonaka, Hiroi ^b   Kanazawa, Yoko ^b   Yoshitome, Eiji ^b   Ikehira, Hiroo ^b   Hashimoto, Kenji ^c   Iyo, Masaomi ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Amino acids; Cognitive control; Medial prefrontal cortex; MRS; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE; BIPERIDEN; CHLORPROMAZINE; DIAZEPAM; GLUTAMIC ACID; GLUTAMINE; GLYCEROPHOSPHORYLCHOLINE; N ACETYLASPARTIC ACID; OLANZAPINE; PEROSPIRONE; PHOSPHORYLCHOLINE; QUETIAPINE; RISPERIDONE; TAURINE;

ADULT; ARTICLE; BRAIN FUNCTION; BRAIN METABOLISM; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; LANGUAGE ABILITY; MALE; METABOLITE; NEUROLOGIC DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOSIS; SCHIZOPHRENIA;

ADULT; AMINO ACIDS; BRAIN CHEMISTRY; COGNITION DISORDERS; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEUROPSYCHOLOGICAL TESTS; PREFRONTAL CORTEX; SCHIZOPHRENIA;

EID: 71849110853     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2009.10.031     Document Type: Article

References (90)

1. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV). Washington, DC.
2. Amodio D.M., and Frith C.D. Meeting of minds: the medial frontal cortex and social cognition. Nat. Rev. Neurosci. 7 (2006) 268-277
3. Andreasen N.C. Negative symptoms in schizophrenia: definition and reliability. Arch. Gen. Psychiatry 139 (1982) 784-788
4. Bartha R., Williamson P.C., Drost D.J., Malla A., Carr T.J., Cortese L., Canaran G., Rylett R.J., and Neufeld R.W. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 54 (1997) 959-965
5. Bechera A., Damasio A.R., Damasio H., and Anderson S.W. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 50 (1994) 7-15
6. Behar K.L., Rothman D.L., Petersen K.F., Hooten M., Delaney R., Petroff O.A.C., Shulman G.I., Nvarro V., Petrakis I.L., Charney D.S., and Krystal J.H. Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. Am. J. Psychiatry 156 (1999) 952-954
7. Blakemore S.J. The social brain in adolescence. Nat. Rev. Neurosci. 9 (2008) 267-277
8. Bonilha L., Molnar C., Horner M.D., Anderson B., Forster L., George M.S., and Nahas Z. Neurocognitive deficits and prefrontal cortical atrophy in patients with schizophrenia. Schizophr. Res. 101 (2008) 142-151
9. Boulanger Y., Labelle M., and Khiat A. Role of phospholipase A2 on the variations of the choline signal intensity observed by 1H magnetic resonance spectroscopy in brain diseases. Brain Res. Rev. 33 (2000) 380-389
10. Bowie C.R., Leung W.W., Reichenberg A., McClure M.M., Patterson T.L., Heaton R.K., and Harvey D. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol. Psychiatry 63 (2008) 505-511
11. Bush G., Luu P., and Posner M.I. Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn. Sci. 4 (2000) 215-222
12. 15O PET study of Stroop task performance. Neuroimage 2 (1995) 264-272
13. 2O PET study during single-trial Stroop task performance. Am. J. Psychiatry 154 (1997) 1670-1675
14. Chan M.W.C., Yip J.T.H., and Lee T.M.C. Differential impairment on measures of attention in patients with paranoid and nonparanoid schizophrenia. J. Psychiatry Res. 38 (2004) 145-152
15. B receptors in rat hippocampal CA1 area. Brain Res. 864 (2000) 298-307
16. Dolan R.J., Fletcher P., Frith C.D., Friston K.J., Frackowiak R.S.J., and Grasby P.M. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 378 (1995) 180-182
17. Dollfus S., Razafimandimby A., Maiza O., Lebain P., Brazo P., Beaucousin V., Lecardeur L., Delamillieure P., Mazoyer B., and Tzourio-Mazoyer N. Functional deficit in the medial prefrontal cortex during a language comprehension task in patients with schizophrenia. Schizophr. Res. 99 (2008) 30-311
18. Elvevåg B., and Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Critic. Rev. Neurobiol. 14 (2000) 1-21
19. Fellows L.K., and Farah M.J. Different underlying impairments in decision-making following ventromedial and dorsolateral frontal lobe damage in humans. Cereb. Cortex 15 (2005) 58-63
20. Fioravanti M., Carlone O., Vitale B., Cinti M.E., and Clare L. A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychology Rev. 15 (2005) 75-95
21. Fuster J.M. The prefrontal cortex-an update: time is of the essence. Neuron 30 (2001) 319-333
22. Goldman-Rakic P.S. Regional and cellular fractionation of working memory. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 13473-13480
23. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 153 (1996) 321-330
24. Green M.F., Marshall Jr. B.D., Wirshing W.C., Ames D., Marder S.R., McGurk S., Kern R.S., and Mintz J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?. Am. J. Psychiatry 154 (1997) 799-804
25. Hashimoto K., Engberg G., Shimizu E., Nordin C., Lindsröm L.H., and Iyo M. Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naïve schizophrenic patients. BMC Psychiatry 5 (2005) 6
26. Hashimoto K., Shimizu E., and Iyo M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr. Psychiatry Rev. 1 (2005) 151-163
27. Heaton R.K., Chelune G.J., Talley J.L., Kay G.G., and Curtiss G. Wisconsin Card Sorting Test Manual (1993), Psychological Assessment Resources, Odessa, FL
28. Heckers S., Weiss A.P., Deckersbach T., Goff D.C., Morecraft R.J., and Bush G. Anterior cingulate cortex activation during cognitive interference in schizophrenia. Am. J. Psychiatry 161 (2004) 707-715
29. Ho B.C., Andreasen N.C., Flaum M., Nopoulos P., and Miller D. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am. J. Psychiatry 157 (2000) 808-815
30. Hori H., Noguchi H., Hashimoto R., Takabayashi T., Omori M., Takahashi S., Tsukue R., Anami K., Hirabayashi N., Harada S., Saitoh O., Iwase M., Kajimoto O., Takeda M., Okabe S., and Kunugi H. Antipsychotic medication and cognitive function in schizophrenia. Schizophr. Res. 86 (2006) 138-146
31. Inada T., Nozaki S., Inagaki A., and Furukawa T.A. Efficacy of diazepam as an anti-anxiety agent: meta-analysis of double-blind, randomized controlled trials carried out in Japan. Human Psychopharmacol. 18 (2003) 483-487
32. Inada T., Yagi G., and Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr. Res. 567 (2002) 227-238
33. Igarashi K., Oguni H., Osawa M., Awaya Y., Kato M., Mimura M., and Kahima H. Wisconsin card sorting test in children with temporal lobe epilepsy. Brain Dev. 24 (2002) 174-178
34. Ingvar D.H., and Franzen G. Distribution of cerebral activity in chronic schizophrenia. Lancet 2 (1976) 1484-1486
35. Johnston K., Levine K.H., Kaval M.J., and Everlling S. Top-down control-signal dynamics in anterior cingulate and prefrontal cortex neurons following task switching. Neuron 53 (2007) 453-462
36. Kibel D.A., Laffont L., and Liddle P.F. The composition of the negative syndrome of chronic schizophrenia. Br. J. Psychiatry 162 (1993) 744-750
37. Kosmidis M.H., Bozikas V.P., Zafiri M., and Karavatos A. Shared cognitive processes underlying performance on the Wisconsin Card Sorting Test and the Stroop Test in patients with schizophrenia: a measurement artifact?. Neurosci. Lett. 409 (2006) 234-238
38. MacDonald A.W., Cohen J.D., Stenger V.A., and Carter C.S. Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science 288 (2000) 1835-1838
39. MacLeod C.M. Half a century of research on the Stroop effect: an integrative review. Psychol. Bull. 109 (1991) 163-203
40. Marshall M., Lewis S., Lockwood A., Drake R., Jones P., and Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch. Gen. Psychiatry 62 (2005) 975-983
41. Mayberg H.S., Lozano A.M., Voon V., McNeely H.E., Seminowicz D., Hamani C., Schwalb J.M., and Kennedy S.H. Deep brain stimulation for treatment-resistant depression. Neuron 45 (2005) 651-660
42. Mentzel H.J., Gaser C., Volz H.P., Rzanny R., Hager F., Sauer H., and Kaiser W.A. Cognitive stimulation with the Wisconsin Card Sorting Test: functional imaging at 1.5 T. Radiology 207 (1998) 399-404
43. Monk C.S., McClure E.B., Nelson E.E., Zarahn E., Bilder R.M., Leibenluft E., Charney D.S., Ernst M., and Pine D.S. Adolescent immaturity in attention-related brain engagement to emotional facial expressions. Neuroimage 20 (2003) 420-428
44. Moser R.K., Cienfuegos A., Barros J., and Javitt D. Auditory distraction and thought disorder in chronic schizophrenic inpatients: evidence for separate contributions by incapacity and poor allocation and subsyndrome related to the allocation deficit. Schizophr. Res. 51 (2001) 163-170
45. Nakamura H., Nakanishi M., Furukawa T.A., Hamanaka T., and Tokudome S. Validity of brief intelligence tests for patients with Alzheimer's disease. Psychiat. Clin. Neurosci. 54 (2000) 435-439
46. Nakamura M., Nestor P.G., Levitt J.J., Cohen A.S., Kawashima T., Shenton M.E., and McCarley R.W. Orbitofrontal volume deficit in schizophrenia and thought disorder. Brain 131 (2008) 180-195
47. Nelson J., and Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Can. J. Clin. Pharmacol. 6 (1999) 69-83
48. Ohrmann P., Kugel H., Bauer J., Siegmund A., Kölkebeck K., Suslow T., Wiedl K.H., Rothermundt M., Arolt V., and Pedersen A. Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy. Schizophr. Res. 106 (2008) 156-163
49. Oltmanns T.F., and Neale J.M. Schizophrenic performance when distractors are present: attentional deficit or differential task difficulty?. J. Abnorm. Psychology 84 (1975) 205-209
50. Ongur D., Cullen T.J., Wolf D.H., Rohan M., Barreira P., Zalesak M., and Heckers S. The neural basis of relational memory deficits in schizophrenia. Arch. Gen. Psychiatry 63 (2006) 356-365
51. Overall J., and Gorham D. The brief psychiatric rating scale. Psychiatry Res. 10 (1961) 799-812
52. Perkins D.O., Gu H., Boteva K., and Lieberman J.A. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am. J. Psychiatry 162 (2005) 1785-1804
53. Polli F.E., Barton J.J.S., Thakkar K.N., Greve D.N., Goff D.C., Rauch S.L., and Manoach D.S. Reduced error-related activation in two anterior cingulate circuits is related to impaired performance in schizophrenia. Brain 131 (2008) 971-986
54. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 30 (1993) 672-679
55. 1H spectra with LCModel. NMR Biomed. 14 (2001) 260-264
56. Purdon S.E., Jones D.W., Stip E.S., Labelle A., Addington D., David S.R., Breier A., and Tollefson G.D. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch. Gen. Psychiatry 57 (2000) 249-258
57. Ramnani N., and Owen A.M. Anterior prefrontal cortex: insight into function from anatomy and neuroimaging. Nat. Rev. Neurosci. 5 (2004) 184-194
58. Ramonet D., Rodriguez M.J., Fredriksson K., Bernal F., and Mahy N. In vivo neuroprotective adaptation of the glutamate/glutamine cycle to neuronal death. Hippocampus 14 (2004) 586-594
59. Reilly J.L., Harris M.S.H., Khine T.T., Keshava M.S., and Sweeney J.A. Reduced attentional engagement contributes to deficits in prefrontal inhibitory control in schizophrenia. Biol. Psychiatry 63 (2008) 776-783
60. Reitan R.M., and Wolfson D. The Halstead-Reitan Neuropsychological Test Battery (1985), Neuropsychology Press, Tucson
61. Ridderinkhof K.R., Ullsperger M., Crone E.A., and Nieuwenhuis S. The role of the medial frontal cortex in cognitive control. Science 306 (2004) 443-447
62. Riehemann S., Volz H.P., Stutzer P., Smesny S., Gaser C., and Sauer H. Hypofrontality in neuroleptic-naïve schizophrenic patients during the Wisconsin Card Sorting Test-a fMRI study. Eur. Arch. Psychiat. Clin. Neurosci. 251 (2001) 66-71
63. Ross B.M., Hudson C., Erlich J., Warsh J.J., and Kish S.J. Increased phospholipids breakdown in schizophrenia: evidence for the involvement of a calcium-independent phospholipase A2. Arch. Gen. Psychiatry 54 (1997) 487-494
64. Sartorius A., Schloss P., Vollmayr B., Ende G., Neumann-Haefelin C., Hoehn M., and Henn F.A. Correlation between MR-spectroscopic rat hippocampal choline levels and phospholipase A2. World J. Biol. Psychiatry 7 (2006) 246-250
65. Schoenbaum G., Roesch M.R., and Stalnaker T.A. Orbitofrontal cortex, decision-making and drug addiction. Trends Neurosci. 29 (2006) 116-124
66. Shad M.U., Tamminga C.A., Cullum M., Haas G.L., and Keshavan M.S. Insight and frontal cortical function in schizophrenia: a review. Schizophr. Res. 86 (2006) 54-70
67. 31P NMR spectroscopy shows an increase in glycerophosphorylcholine concentration without alterations in mitochondrial function in the prefrontal cortex of medicated schizophrenic patients at rest. Eur. J. Neurosci. 20 (2004) 749-756
68. Shulman Y., Grant S., Seres P., Hanstock C., Baker G., and Tibbo P. The relation between peripheral and central glutamate and glutamine in healthy male volunteers. J. Psychiatry Neurosci. 31 (2006) 406-410
69. Silver H., and Geraisy N. Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients, a double blind cross-over study. Br. J. Psychiatry 166 (1995) 241-243
70. Simon A.E., Cattapan-Ludewig K., Zmilacher S., Arbach D., Gruber K., Dvorsky D.N., Roth B., Isler E., Zimmer A., and Umbricht D. Cognitive functioning in the schizophrenia prodrome. Schizophr. Bull. 33 (2007) 761-771
71. Smesny S., Kinder D., Willhardt I., Rosburg T., Lasch J., Berger G., and Sauer H. Increased calcium-independent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia. Biol. Psychiatry 57 (2005) 399-405
72. 1H spectroscopy study. Schizophr. Res. 93 (2007) 23-32
73. Stark A.K., Uylings H.B.M., Sanz-Arigita E., and Pakkenberg B. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am. J. Psychiatry 161 (2004) 882-888
74. 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 30 (2005) 1949-1962
75. Sumiyoshi C., Sumiyoshi T., Nohara S., Yamashita I., Matsui M., Kurachi M., and Niwa S. Disorganization of semantic memory underlies alogia in schizophrenia: an analysis of verbal fluency performance in Japanese subjects. Schizophr. Res. 74 (2005) 91-100
76. 1H-MRS). Schizophr. Res. 108 (2009) 69-77
77. Tebartz van Elst L., Valerius G., Büchert M., Thiel T., Rüsch N., Bubl E., Hennig J., Ebert D., and Olbrich HM. Increased prefrontal and hippocampal glutamate concentration in schizophrenia evidence from a magnetic resonance spectroscopy study. Biol. Psychiatry 58 (2005) 724-730
78. Théberge J., Bartha R., Drost D.J., Menon R.S., Malla A., Takhar J., Neufeld R.W., Rogers J., Pavlosky W., Schaefer B., Densmore M., Al-Semaan Y., and Williamson P.C. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am. J. Psychiatry 159 (2002) 1944-1946
79. Théberge J., Al-Semaan Y., Williamson P.C., Menon R.S., Neufeld R.W., Rajakumar N., Schaefer B., Densmore M., and Drost D.J. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison measured with 4.0 T proton MRS. Am. J. Psychiatry 160 (2003) 2231-2233
80. Volk D.W., and Lewis D.A. GABA targets for the treatment of cognitive dysfunction in schizophrenia. Curr. Neuropharmacology 3 (2005) 45-62
81. Warner T.D., Behnke M., Eyler F.D., Padgett K., Leonard C., Hou W., Garvan C.W., Schmalfuss I.M., and Blackband S.J. Diffusion tensor imaging of frontal white mater and executive functioning in cocaine-exposed children. Pediatrics 118 (2006) 2014-2024
82. Watanabe M., Ohe Y., Katakai K., Kabeya K., Fukunura Y., Kobayashi I., Miyamoto K., and Ichikawa K. Glutamine is involved in the dependency of brain neuron survival on cell plating density in culture. Neuroreport 9 (1998) 2353-2357
83. Wechsler D. Wechsler Adult Intelligence Scale. 3rd ed (1997), San Antonio, TX, Psychological Corporation
84. Weinberger D.R. Schizophrenia and the frontal lobe. Trends Neurosci. 11 (1988) 367-370
85. Wood S.J., Yücel M., Wellard R.M., Harrison B.J., Clarke K., Fornito A., Velakoulis D., and Pantelis C. Evidence for neuronal dysfunction in the anterior cingulated of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3T. Schizophr. Res. 94 (2007) 328-331
86. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 64 (2003) 663-667
87. Woodward N.D., Purdon S.E., Meltzer H.Y., and Zald D.H. A meta-analysis of neuropsychological change to clozpapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8 (2005) 457-472
88. Yamasue H., Fukui T., Fukuda R., Yamada H., Yamasaki S., Kuroki N., Abe O., Kasai K., Tsujii K., Iwanami A., Aoki S., Ohtomo K., Kato N., and Kato T. 1H-MR spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia. Neuroreport 13 (2002) 2133-2137
89. Yücel M., Pantelis C., Stuart G.W., Wood S.J., Maruff P., Velakoulis D., Pipingas A., Crowe S.F., Tochon-Danguy H.J., and Egan G.F. Anterior cingulate activation during Stroop task performance: a PET to MRI coregistration study of individual patients with schizophrenia. Am. J. Psychiatry 159 (2002) 251-254
90. Zakzanis K.K., Mraz R., and Graham S.J. An fMRI study on the Trail Making Test. Neuropsychologia 43 (2005) 1878-1886